Clinical Overview
Molindone was a dihydroindolone antipsychotic indicated for the management of schizophrenia. Important Note: This medication was discontinued by its manufacturer (Endo Pharmaceuticals) in 2010, and while generic versions may still be available in limited markets, it is generally no longer accessible for new prescriptions.
Historical Clinical Applications
Molindone was used for schizophrenia management and was notable among typical antipsychotics for causing less weight gain and having a lower risk of tardive dyskinesia compared to phenothiazines. It was sometimes preferred for patients concerned about metabolic side effects.
Mechanism and Characteristics
As a dopamine D2 receptor antagonist, molindone provided antipsychotic efficacy similar to other typical antipsychotics but with a unique chemical structure (dihydroindolone) that contributed to its distinct side effect profile, including potential for weight loss rather than gain.
Current Status
Due to discontinuation by the manufacturer, molindone is no longer readily available. Patients previously on molindone should be transitioned to alternative antipsychotics under medical supervision, with consideration of their previous response and tolerability profile.
Prescribing Information
Market Status
- DISCONTINUED: Brand name Moban discontinued in 2010
- Limited availability: Some generic versions may exist
- Reason: Commercial decision by manufacturer
- Current Recommendation: Use alternative antipsychotics
Historical Indications
- Schizophrenia management
- Psychotic disorders
Historical Dosing (when available)
Schizophrenia:
- Initial: 50-75 mg daily
- Increase to: 100 mg daily in 3-4 days
- Range: 50-225 mg daily
- Severe cases: Up to 400 mg daily
Contraindications
- All patients – medication generally discontinued
- Previously contraindicated in: severe CNS depression, comatose states
Warnings & Precautions
- DISCONTINUED: Limited availability for new prescriptions
- Historical concerns: Tardive dyskinesia, extrapyramidal symptoms
- Notable difference: Less weight gain than other typical antipsychotics
- Neuroleptic malignant syndrome risk
Alternative Treatments
Recommended Alternatives:
- Atypical antipsychotics: Risperidone, olanzapine, quetiapine, aripiprazole
- Other typical antipsychotics: Haloperidol, fluphenazine (if typical preferred)
- For weight concerns: Aripiprazole, ziprasidone, lurasidone
- Long-acting options: Paliperidone palmitate, risperidone LAI
Transition Considerations
- Gradual cross-titration from molindone to alternative
- Monitor for symptom recurrence during transition
- Consider patient’s previous response to molindone
- Address metabolic monitoring if switching to atypical antipsychotic
Special Populations
- All Populations: Medication generally no longer available
- Historical Advantage: Lower weight gain risk compared to other antipsychotics
- Previous Use: Required monitoring for extrapyramidal symptoms
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
